Citius Oncology Reports $3.9M in First Revenue from LYMPHIR Launch
Event summary
- Citius Oncology reported $3.9M in revenue from LYMPHIR sales in Q1 2026, its first commercial revenue.
- LYMPHIR, an FDA-approved immunotherapy for CTCL, launched in December 2025.
- Company raised $15.1M in December 2025 through a registered offering.
- Net loss narrowed to $5.5M in Q1 2026 from $6.7M in the prior-year period.
The big picture
Citius Oncology's transition to a commercial-stage oncology company marks a significant milestone in its strategic evolution. The successful launch of LYMPHIR positions the company to tap into a growing, underserved market estimated at over $400 million. The deployment of an AI-enabled commercial platform underscores the company's focus on efficient market penetration in a highly concentrated prescriber base.
What we're watching
- Market Penetration
- How Citius Oncology will accelerate physician adoption and expand patient access for LYMPHIR.
- Strategic Opportunities
- Whether Citius Oncology can leverage its AI-enabled commercial platform to drive efficient market penetration.
- Financial Sustainability
- The pace at which Citius Oncology can sustain its revenue growth and manage its cash position.
Related topics